Pharmaceutical - Cardio-vascular, Metabolics

Filter

Current filters:

Cardio-vascularMetabolics

Popular Filters

AstraZeneca in research accord with Max Planck Institute

AstraZeneca in research accord with Max Planck Institute

08-07-2014

Anglo-Swedish pharma major AstraZeneca has entered an agreement with the Max Planck Institute of Molecular…

AstraZenecaCardio-vascularMetabolicsPharmaceuticalResearch

Ligand licenses five programs to Viking Therapeutics

23-05-2014

US drugmaker Ligand Pharmaceuticals has out-licensed rights to five programs to Viking Therapeutics,…

Cardio-vascularDiabetesFinancialLicensingLigand PharmaceuticalsMetabolicsPharmaceuticalViking Therapeutics

Sanford-Burnham and Daiichi Sankyo collaborate on novel cardiovascular-metabolic diseases drug targets

22-05-2014

USA-based Sanford-Burnham Medical Research Institute and Japanese drug major Daiichi Sankyo have entered…

Cardio-vascularDaiichi SankyoMetabolicsPharmaceuticalResearch

AstraZeneca stresses confidence in independence, highlighting strong R&D pipeline

15-05-2014

Anglo-Swedish pharma major AstraZeneca, the subject of the controversial takeover attempt by Pfizer,…

AstraZenecaCardio-vascularMergers & AcquisitionsMetabolicsOncologyPharmaceuticalResearchRespiratory and Pulmonary

MedImmune joins research collaboration with the University of California

MedImmune joins research collaboration with the University of California

17-02-2014

MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

Antibiotics and Infectious diseasesCardio-vascularInflammatory diseasesMedImmuneMetabolicsNeurologicalOncologyPharmaceuticalResearchRespiratory and PulmonaryUSA

AstraZeneca acquires AlphaCore; Merck Serono links with BioMed X

03-04-2013

In line with its stated policy of targeted acquisitions, Anglo-Swedish drug major AstraZeneca (LSE: AZN)…

AlphaCore PharmaAstraZenecaBiotechnologyCardio-vascularMerck KGaAMerck SeronoMergers & AcquisitionsMetabolicsPharmaceuticalResearch

AstraZeneca aligns with Regulus for microRNA therapeutics

16-08-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US biotech firm Regulus Therapeutics have signed…

AstraZenecaBiotechnologyCardio-vascularLicensingMetabolicsPharmaceuticalRegulus Therapeutics

Scripps researchers create compounds with potential to treat range of disorders, inc obesity and diabetes

01-04-2012

Scientists from the Florida, USA, campus of The Scripps Research Institute have synthesized a pair of…

Cardio-vascularDiabetesMetabolicsPharmaceuticalResearch

B-MS ties knot with Duke University on R&D

29-02-2012

Bristol-Myers Squibb has forged a partnership with Duke University in the USA that will see the academic…

Bristol-Myers SquibbCardio-vascularGeneralHomeLysophosphatidic acid 1 (LPA1)MetabolicsOncologyPfizerPharmaceuticalRespiratory and PulmonarySanofi

EMA turns positive on orlistat and aprotinin; CHMP backs Pixuvri

20-02-2012

Finalizing its review on orlistat-containing medicines and the possible risk of severe liver injuries,…

AlliBayerBiotechnologyCardio-vascularCell TherapeuticsEuropeGlaxoSmithKlineMetabolicsOncologyorlistatPharmaceuticalPixuvriRegulationRocheTrasylolXenical

Cornerstone acquires Cardiokine

04-01-2012

US specialty drugmaker Cornerstone Therapeutics (Nasdaq: CRTX) said yesterday that it has acquired Cardiokine,…

Cardio-vascularCardiokineCornerstone TherapeuticslixivaptanMergers & AcquisitionsMetabolicsPharmaceutical

Back to top